Gareth Lugg

February 23, 2026
ROME & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. The collaboration brings together Quiver’s unique drug discovery capabilities, data assets, and AI models with Angelini Pharma’s established expertise in brain health and epilepsy drug development.

Freienbach, January 8^th 2026 – EffRx Pharmaceuticals SA, a Swiss commercial-stage pharmaceutical company focused on the development and commercialization of treatments for endocrine, metabolic and musculoskeletal disorders, today announced the signing of an exclusive licensing and distribution agreement with Compai Pharma for the commercialization of Binosto^® in Malaysia. Compai Pharma is a leading medical distribution company with strong reach across South East Asia.